Search results
Results from the WOW.Com Content Network
The particular PEGylated molecule in the Moderna vaccine is known as DMG-PEG 2000. Pegvaliase (Biomarin) – PEGylated recombinant phenylalanine ammonia-lyase for the treatment of Phenylketonuria, approved by the FDA for the US in May 2018. [22] [23] Adynovate – PEGylated Antihemophilic Factor VIII for the treatment of patients with hemophilia A.
diabetes Crovalimab [53] Piasky: mab: humanized: C5: Y: paroxysmal nocturnal hemoglobinuria: CR6261: mab: human: Hemagglutinin (influenza) infectious disease/influenza A Cusatuzumab [5] mab: humanized: CD70: cancer Dacetuzumab [13] mab: humanized: CD40: hematologic cancers Daclizumab [54] Zenapax: mab: humanized: CD25 (α chain of IL-2 receptor) Y
Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery. [3] Also used to treat hepatitis C (typically, in combination with ribavarin ), it is no longer recommended due to poor efficacy and adverse side-effects. [ 4 ]
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. [3] For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. [3] [4] For hepatitis B it may be used alone. [5] It is given by injection under the skin. [3] Side effects ...
Special pages; Permanent link; Page information; Cite this page; Get shortened URL; ... It is developed by Carmot Therapeutics for diabetes and obesity. [1] [2 ...
Pegylated interferon-alpha-2b; Pegylated interferon beta-1a [2] In these formulations, Polyethylene glycol (PEG) is added to make interferon last longer in the body. [3] They are used to treat both hepatitis B, [4] hepatitis C [1] and multiple sclerosis. [2] Pegylated interferon is contraindicated in patients with hyperbilirubinaemia. [citation ...
Phenylalanine ammonia lyase is specific for L-phenylalanine, and to a lesser extent, L-tyrosine. [9] [10] The reaction catalyzed by PAL is a spontaneous elimination reaction rather than an oxidative deamination.
A fasting blood sugar level of ≥ 7.0 mmol / L (126 mg/dL) is used in the general diagnosis of diabetes. [17] There are no clear guidelines for the diagnosis of LADA, but the criteria often used are that the patient should develop the disease in adulthood, not need insulin treatment for the first 6 months after diagnosis and have autoantibodies in the blood.